These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 35183936

  • 1. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
    Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L, Kristensen LE, Thyssen JP, Thomsen SF, Cordtz RL, Loft N, Skov L, Bryld LE, Rasmussen MK, Højgaard P, Kristensen S, Dreyer L.
    Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
    [Abstract] [Full Text] [Related]

  • 2. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents.
    Kerola AM, Rollefstad S, Kazemi A, Wibetoe G, Sexton J, Mars N, Kauppi M, Kvien TK, Haavardsholm EA, Semb AG.
    Scand J Rheumatol; 2023 Jan; 52(1):42-50. PubMed ID: 35014920
    [Abstract] [Full Text] [Related]

  • 3. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
    Iannone F, Favalli EG, Caporali R, D'Angelo S, Cantatore FP, Sarzi-Puttini P, Foti R, Conti F, Carletto A, Gremese E, Cauli A, Ramonda R, Palermo A, Epis O, Priora M, Bergossi F, Frediani B, Salaffi F, Lopalco G, Cacciapaglia F, Marchesoni A, Biggioggiero M, Bugatti S, Balduzzi S, Carriero A, Corrado A, Bongiovanni S, Benenati A, Miranda F, Fracassi E, Perra D, Ferraccioli G, Lapadula G.
    Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
    [Abstract] [Full Text] [Related]

  • 4. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P, Psaltis D, Georgiadis A, Katsifis G, Theodoridou A, Gazi S, Sidiropoulos P, Tektonidou MG, Bounas A, Kandyli A, Vounotrypidis P, Sakellariou GT, Vassilopoulos D, Huang Z, Petrikkou E, Boumpas D.
    Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
    [Abstract] [Full Text] [Related]

  • 5. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M, Righetti G, Abbruzzese A, Lopalco G, Cacciapaglia F, Anelli MG, Venerito V, Iannone F.
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [Abstract] [Full Text] [Related]

  • 6. Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis - data from the Danish nationwide DANBIO registry.
    Mathew AJ, Glintborg B, Krogh NS, Hetland ML, Østergaard M.
    Semin Arthritis Rheum; 2022 Feb; 52():151948. PubMed ID: 35027245
    [Abstract] [Full Text] [Related]

  • 7. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
    Pombo-Suarez M, Sanchez-Piedra C, Garcia-Magallón B, Pérez-Gómez A, Manrique-Arija S, Martín-Doménech R, Colazo M, Campos C, Campos J, Del Pino-Montes J, Arteaga MJ, Cea-Calvo L, Díaz-González F, Gómez-Reino JJ.
    Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
    [Abstract] [Full Text] [Related]

  • 8. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E, Baraliakos X, Behrens F, Thaçi D, Plenske A, Klaus P, Meng T.
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [Abstract] [Full Text] [Related]

  • 9. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW.
    J Med Econ; 2016 Apr; 19(1):34-43. PubMed ID: 26337538
    [Abstract] [Full Text] [Related]

  • 10. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS.
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [Abstract] [Full Text] [Related]

  • 11. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark.
    Secher AEP, Granath F, Glintborg B, Rom A, Hetland ML, Hellgren K.
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328400
    [Abstract] [Full Text] [Related]

  • 12. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehøj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sørensen MV, Andersen LS, Grøn KL, Krogh NS, Pedersen L, Hetland ML, all departments of rheumatology in Denmark.
    Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
    [Abstract] [Full Text] [Related]

  • 13. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM, BADBIR Study Group.
    JAMA Dermatol; 2022 Oct 01; 158(10):1131-1141. PubMed ID: 35791876
    [Abstract] [Full Text] [Related]

  • 14. Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry.
    Lindström Egholm C, Krogh NS, Pincus T, Dreyer L, Ellingsen T, Glintborg B, Kowalski MR, Lorenzen T, Madsen OR, Nordin H, Rasmussen C, Hetland ML.
    J Rheumatol; 2015 Oct 01; 42(10):1781-5. PubMed ID: 26233511
    [Abstract] [Full Text] [Related]

  • 15. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
    Govoni M, Batalov A, Boumpas DT, D'Angelo S, De Keyser F, Flipo RM, Kellner H, Leroi H, Khalifa A.
    Clin Exp Rheumatol; 2024 Mar 01; 42(3):642-650. PubMed ID: 37976120
    [Abstract] [Full Text] [Related]

  • 16. Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States.
    Hopson S, Gibbs LR, Syed S, Low R, McClung L, Beaty S.
    Adv Ther; 2023 Oct 01; 40(10):4358-4376. PubMed ID: 37486558
    [Abstract] [Full Text] [Related]

  • 17. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.
    Semin Arthritis Rheum; 2017 Oct 01; 47(2):183-192. PubMed ID: 28413099
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.
    BioDrugs; 2017 Aug 01; 31(4):299-316. PubMed ID: 28612180
    [Abstract] [Full Text] [Related]

  • 19. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D'Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G.
    Semin Arthritis Rheum; 2017 Aug 01; 47(1):108-114. PubMed ID: 28216195
    [Abstract] [Full Text] [Related]

  • 20. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
    Michelsen B, Sexton J, Wierød A, Bakland G, Rødevand E, Krøll F, Kvien TK.
    Semin Arthritis Rheum; 2020 Feb 01; 50(1):12-16. PubMed ID: 31358361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.